KUALA LUMPUR, April 23 (Bernama) -- The 46th session of King Faisal Prize has acknowledged exceptional accomplishments in the fields of gene therapy for neuromuscular diseases and groundbreaking Ribonucleic acid (RNA) discoveries. Revolutionary scientist Professor Jerry Mendell was awarded the Medicine Prize for his groundbreaking contributions to the screening, early diagnosis, and treatment of neuromuscular disorders, notably spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). Meanwhile, Professor Howard Chang received the Science Prize for unveiling the intrinsic role of long non-coding RNAs in gene regulation and function, a previously overlooked area of study, according to a statement. Through innovative gene therapy approaches, Professor Mendell, a Director of Gene Therapy Center at Nationwide Children’s Hospital and Curran Peters Chair in Pediatric Research, has revolutionised treatment strategies, offering hope to countless patients worldwide. On the frontier of molecular biology, physician-scientist and Professor of Dermatology and Genetics, and Virginia and D.K. Ludwig Professor of Cancer Research at Stanford University, Professor Chang's elucidation of the role of long non-coding RNAs (lncRNAs) in gene regulation has revolutionised the understanding of cellular processes and disease mechanisms. Through innovative genome-wide methodologies, Professor Chang has uncovered the intricate interplay between lncRNAs and gene expression, shedding light on fundamental biological processes underlying development, cancer, and ageing. In addition to honouring advancements in medicine and science, the King Faisal Prize also recognised exemplary contributions in Islamic Studies to Professor Wael Hallaq, while the Japan Muslim Association and Mohammad El Sammak were honoured for their exemplary leadership in serving Islam and humanity. King Faisal Prize for Arabic Language & Literature for 2024 on the topic of “Non-Arab Institutions and their Endeavors to Promote Arabic” was withheld due to nominated works not elevating to the criteria of the prize. Launched by the King Faisal Foundation and granted for the first time since 1979, King Faisal Prize in its five different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes. Each prize laureate is endowed with US$200,000; a 24-carat gold medal weighing 200 grammes, and a Certificate inscribed with the Laureate’s name and a summary of their work which qualified them for the prize. (US$1=RM4.77) -- BERNAMA
0 Comments
BOSTON, April 19 (Bernama-GLOBE NEWSWIRE) -- Anaqua, the leading provider of innovation and intellectual property (IP) management technology for corporations, law firms and governments, announces advancements in its Foreign Filing offering, enhancing the capabilities of its IP management platform, AQX®. Anaqua has shifted the paradigm of foreign filing for IP professionals from a burdensome set of manual administrative tasks to a strategic and automated differentiator, powering rapid decision-making for global IP protection.
In today’s competitive landscape, global IP practitioners understand the critical importance of protecting their innovation and inventions across borders. Anaqua’s advanced Foreign Filing within AQX offers a centralized ecosystem that addresses every aspect of the foreign filing lifecycle. On the AQX platform, customers can now utilize a decision workspace supported by competitive dashboards, foreign filing-specific reports, and online quoting to develop, execute, track, and manage their foreign filings. IP professionals can access a network of expert jurisdictional associates and translation providers to further improve the filing processes with transparent pricing and visibility into the process. mrem.bernama.com/viewsm.php?idm=48419 KUALA LUMPUR, Malaysia, April 19 (Bernama-BUSINESS WIRE) -- Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/ Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, with this launch, it is now expanding its presence to other stores, starting with Steam. Evgenii Romin, Publishing Director at Long Tale Games, expressed his enthusiasm for the forthcoming relaunch and the accompanying campaign by saying, "We are incredibly excited to introduce 'Life is Feudal: MMO' to a broader audience via Steam. In addition, we're eager to show our gratitude towards our community through the balance restoration campaign. This endeavor demonstrates our appreciation for our players' support and mirrors our dedication to ensuring a fair and rewarding gaming experience." Life is Feudal: MMO has been significantly refined through relentless development, targeted rebalancing, and the elimination of bugs while maintaining a strong bond with its community, with a special nod to the contributions of modders. The game has experienced a renaissance with over 150 updates to its content, including new items, buildings, professions, and gameplay mechanics, along with the introduction of much-anticipated features like in-game voice chat, anti-cheat systems, and additional content. These advancements and captivating events, such as the King of the Hill competition, have profoundly enriched the gaming experience. Thank you to the players and the MMO community for their dedication to our favorite real-life Medieval simulator. Looking ahead, the roadmap for Life is Feudal: MMO includes major updates inspired by the community's feedback, such as a new map and many game improvements scheduled for mid-2024. This strategy underscores LTG's commitment to developing Life is Feudal: MMO in close cooperation with the community. What is Life is Feudal: MMO? Life is Feudal: MMO is a sandbox MMORPG set in a gritty medieval world called Abella. Players find themselves in this strange new world with no memory of their past and must quickly learn the basics of survival, from hunting and gathering to finding allies who will support them in their time of need. As their journey progresses, players will be able to learn new skills that allow them to craft intricate weapons, construct buildings, and even establish towns, castles, and mighty fortresses. Whether players choose to band together in guilds and march out on epic wars of conquest or master the art of solo survival, the game offers endless opportunities for explorations and conquest, no matter what path they set out on. About Long Tale Games Long Tale Games (LTG) is a multiverse publisher set on reinvigorating legendary games with fresh energy and employing innovative monetization and user acquisition techniques. With a diverse portfolio that includes everything from classic to web3 games, LTG leverages industry expertise to channel, port, further develop, and support the marketing of hidden gems and classics, ensuring each project gets a tailored approach. At its core, LTG is powered by dedicated industry veterans who believe in a community-driven strategy, involving players in the development process to breathe new life into every game, proving their dedication to reviving beloved titles and fostering the growth of new ventures in the gaming world. For additional information and to learn more, please visit corp.ltg.com The monetization model: $14.99 monthly subscription, with a 7-day free trial for new users and 30 days for owners of the original Life is Feudal: MMO on Steam. View source version on businesswire.com: https://www.businesswire.com/news/home/20240418169927/en/ Contact Derrick Stembridge Global Director of Public Relations, LTG [email protected] Source : Long Tale Games --BERNAMA KUALA LUMPUR, Malaysia, April 19 (Bernama-GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC’s commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.
Background: · MRNA Scientific Sdn Bhd: o A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling. MRNA’s innovative techniques enable early disease detection, personalized health management, and AI-driven insights. · Ascension Innovation Sdn Bhd (AISB): o AISB is a trailblazer in healthcare technology, committed to enhancing patient experiences and outcomes. o Their flagship platform, aiCMS, empowers clinics, physicians, and patients to have better control over healthcare delivery through personalized patient health management. Strategic Investment and Handover Ceremony: · MRNA Scientific’s investment of RM 1.2 million (approx. USD $250k) will occur in two tranches. The Company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement. Our investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion. · The infusion of capital will further AISB’s development and accelerate its AI rollout, including: o AI Assistance in the Clinic and on-App: The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings. o Predictive Analytics and Personalized Solutions: aiCMS will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis. Ceremony Participants: · MRNA Scientific Directors: o Mr. Kenny Lai o Mr. CC Wong · AISB Directors: o Mr. Andrew Teng (Chief Executive Officer, CEO) o Mrs. Penny Attenbrough (Chief Strategy Officer, CSO) Expanding Market Reach: · MRNA Scientific and BGLC believe that this strategic investment will allow BGLC’s Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB’s aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients. · By combining MRNA’s expertise in genomics and AISB’s innovative platform, patients and healthcare professionals will benefit from advanced diagnostics and personalized care. Digital Health & AI Market: · The global digital health market size was estimated at USD 240.9 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 2030¹. · The global market size for AI in Healthcare is expected to reach USD 187.7 billion by 2030 with a compound annual growth rate (CAGR) of 38.5% from 2024 to 2030². · Given the market size and opportunities in Digital Health and AI in Healthcare, MRNA and BGLC will closely consider opportunities to increase our participation in this market, including the potential to increase our investment in AISB and other technology platforms. AISB’s Projections: · Projected Revenue in Malaysia: o As stated in its investment documents, AISB anticipates substantial revenue growth driven by increased adoption of aiCMS, with projections reaching RM 75million collectively for 2024-2028. o The platform’s comprehensive suite of services positions it as a game-changer in the Malaysian healthcare landscape. o These revenue projections were part of the approved prospectus on the Securities Commission of Malaysia approved pitchIN Funding platform. · Clinics and Service Providers: o AISB aims to onboard a significant number of healthcare and wellness providers, and corporations. o Since its recent launch, aiCMS has already proven market traction with over 30 healthcare providers and corporations in its initial segue into this broad market. · User Base and Health Records: o With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market. o The platform’s scalability has the potential for exponential growth. Quotes: · Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation: “Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI.” · Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd: “We welcome MRNA Scientific’s support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions.” The handover ceremony took place at the Apollo Men’s Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC). About BioNexus Gene Lab Corporation: BioNexus Gene Lab Corporation (NASDAQ: BGLC) is a global leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes. For more information, visit BioNexus Gene Lab Corp.’s website: www.bionexusgenelab.com About Ascension Innovation Sdn Bhd: Ascension Innovation Sdn Bhd (AISB) is at the forefront of healthcare technology, driving innovation through its flagship platform, aiCMS. For more information, visit Ascension Innovation Sdn Bhd’s website: www.aisb.io ¹ https://www.grandviewresearch.com/industry-analysis/digital-health-market ² https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market For media inquiries, please contact: Investor Relations BioNexus Gene Lab Corporation Email: [email protected] Disclaimer: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or projected. Forward-looking statements include, but are not limited to, statements regarding: · Projected revenue growth · Market trends and adoption rates · The potential impact of aiCMS on patient care These forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from the statements made. Such risks and uncertainties include, but are not limited to: 1. Market and Industry Risks: - Rapidly evolving healthcare technology landscape - Regulatory changes and compliance challenges - Competitive pressures and market dynamics 2. Operational and Financial Risks: - Execution of strategic initiatives - Financial performance and liquidity - Intellectual property protection 3. External Factors: - Global economic conditions - Public health crises (e.g., pandemics) - Political and geopolitical uncertainties Investors are cautioned not to place undue reliance on these forward-looking statements. BGLC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. The safe harbor provisions of the Private Securities Litigation Reform Act of 1995 protect forward-looking statements from litigation risks. Investors are encouraged to review BGLC's filings with the Securities and Exchange Commission (SEC) for a comprehensive understanding of the company's business, financial performance, and risk factors. BioNexus Gene Lab Corporation Tower B, Vertical Business Suite 10-2 No. 8, Jalan Kerinchi, Bangsar South, 59200, Kuala Lumpur Note to Editors: High-resolution images and additional information are available upon request. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c3545c8-1c0f-47c1-aabc-7a3e4d1de620 Source: BioNexus Gene Lab Corp. --BERNAMA KUALA LUMPUR, April 17 (Bernama) -- Association of Certified Anti-Money Laundering Specialists (ACAMS), an international membership organisation dedicated to fight against illicit finance, will hold a two-day anti-financial crime (AFC) training and networking event beginning April 22 at Kerry Hotel, Hong Kong.
According to ACAMS in a statement, the Assembly Asia Pacific (APAC) 2024 will offer attendees expert guidance and practical insights, addressing how the region’s AFC professionals can prepare for the latest regulations and meet compliance expectations. The event will cover timely topics, from complex sanctions that can leave financial institutions grappling with conflicts of law, to technological developments including artificial intelligence that yield new opportunities and challenges. ACAMS Chief Executive Officer, Neil Sternthal said the event will offer invaluable insights essential for compliance professionals grappling with growing regulatory requirements and emerging illicit-finance threats that continue to reshape how AFC compliance is conducted. "But in addition to highlighting the most significant AFC threats and revealing best practices and pathways to capacity building, the event will, importantly, facilitate meaningful conversations and networking opportunities," he said. There will be a deep dive into APAC's evolving compliance landscape, addressing ways to prepare for the Financial Action Task Force's (FATF) fifth round of mutual evaluations, mitigate export control evasion risks, understand recent regulatory developments pertaining to virtual asset service providers (VASPs), and learn about domestic and global efforts to investigate and deter fraud. The Assembly APAC 2024 will feature a session wherein regulators will share their views on current developments in the region. More than 50 speakers will also address timely topics such as ‘pig butchering’ and other scams, conflicts linked to sanctions and emerging geopolitical risk, and a thorough examination of Korea's Travel Rule implementation. More information on Assembly APAC 2024 is available at https://www.acams.org/en/events/the-assembly/the-assembly-apac. -- BERNAMA |
Archives
April 2023
|